Pharmaceutical Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered under Medicare Part D for price negotiations. US antiviral giant Gilead Sciences is broadening its therapeutics focus with a deal for LEO Pharma’s small molecule oral STAT6 program in the area of inflammatory diseases.US healthcare giant Johnson & Johnson announced its planned $14.6 billion acquisition of Intra-Cellular Therapies, along with its already marketed CNS drug Caplyta. USA-based Keros Therapeutics revealed it is termination another Phase II study of its pulmonary arterial hypertension (PAH) candidate cibotercept. Also, Italy’s Newron Pharmaceuticals out-licensed its CNS drug evenamide to South Korea’s Myung In Pharma, having just recently licensed the drug to EA Pharma, a unit of Japan’s Eisai. 19 January 2025